<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00553410</url>
  </required_header>
  <id_info>
    <org_study_id>IBCSG 35-07 / BIG 1-07</org_study_id>
    <secondary_id>2007-001370-88</secondary_id>
    <secondary_id>CDR0000574249</secondary_id>
    <nct_id>NCT00553410</nct_id>
  </id_info>
  <brief_title>Letrozole in Preventing Cancer in Postmenopausal Women Who Have Received 4-6 Years of Hormone Therapy for Hormone Receptor-Positive, Lymph Node-Positive, Early-Stage Breast Cancer</brief_title>
  <acronym>SOLE</acronym>
  <official_title>SOLE, Study of Letrozole Extension, A Phase III Trial Evaluating the Role of Continuous Letrozole Versus Intermittent Letrozole Following 4 to 6 Years of Prior Adjuvant Endocrine Therapy for Postmenopausal Women With Hormone-Receptor Positive, Node Positive Early Stage Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>International Breast Cancer Study Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Breast International Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>International Breast Cancer Study Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Estrogen can cause the growth of breast cancer cells. Letrozole may fight breast
      cancer by lowering the amount of estrogen the body makes. It is not yet known which regimen
      of letrozole is more effective in postmenopausal women who have received hormone therapy for
      early-stage breast cancer.

      PURPOSE: This randomized phase III trial is comparing two different regimens of letrozole in
      preventing cancer in postmenopausal women who have received 4-6 years of hormone therapy for
      hormone receptor-positive, lymph node-positive, early-stage breast cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Compare the disease-free survival (DFS) of postmenopausal women treated with continuous
           letrozole for 5 years vs intermittent letrozole over a 5-year period.

      Secondary

        -  Compare overall survival of patients treated with these two regimens.

        -  Compare distant DFS of these patients.

        -  Compare breast cancer-free interval of these patients.

        -  Compare sites of first DFS failure in these patients.

        -  Compare second (nonbreast) malignancies in these patients.

        -  Compare deaths without prior cancer events in these patients.

        -  Compare adverse events resulting from these two regimens.

      OUTLINE: This is a multicenter study. Patients are stratified according to treatment center
      and type of prior endocrine therapy (selective estrogen receptor modulators [SERMs] alone vs
      aromatase inhibitors [AIs] alone vs both SERMs and AIs each for at least 1 month). Patients
      are randomized to 1 of 2 treatment arms.

        -  Arm I: Patients receive oral letrozole daily for 5 years.

        -  Arm II: Patients receive oral letrozole daily for the first 9 months of years 1 through
           4, followed by 12 months in year 5.

      After completion of study therapy, patients are followed annually.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2007</start_date>
  <completion_date type="Actual">May 15, 2019</completion_date>
  <primary_completion_date type="Actual">April 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease-free Survival (DFS)</measure>
    <time_frame>5-year estimates, reported at a median follow-up of 60 months</time_frame>
    <description>Duration of time from randomization to the first indication of the following events: invasive recurrence at local (including recurrence restricted to the breast after breast conserving treatment), regional or distant sites; a new invasive cancer in the contralateral breast; any second (non-breast) invasive malignancy; or a death without prior cancer event. Appearance of DCIS or LCIS either in the ipsilateral or in the contralateral breast was not be considered as an event for DFS. In the absence of an event, DFS was censored at the date of last follow-up visit.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>5-year estimates, reported at a median follow-up of 60 months</time_frame>
    <description>Duration of time from randomization to death from any cause, or was censored at the date last known alive. (Note, for patients who withdrew consent or were lost to follow-up but follow-up for survival was possible through hospital or registry records, OS was censored at the date last known alive rather than date of last follow-up/withdrawn consent).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distant Recurrence-free Interval (DRFI)</measure>
    <time_frame>5-year estimates, reported at a median follow-up of 60 months</time_frame>
    <description>Duration of time from randomization to the first indication of invasive breast recurrence at a distant site. In the absence of an event, DRFI was censored at the date of last follow-up visit or date or death without distant recurrence.*
*This endpoint replaced DDFS, which was specified in the protocol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Breast Cancer-free Interval</measure>
    <time_frame>5-year estimates, reported at a median follow-up of 60 months</time_frame>
    <description>Duration of time from randomization to the first indication of the following events: invasive breast recurrence at local, regional or distant sites; a new invasive cancer in the contralateral breast (second non-breast malignancies are ignored). In the absence of an event, BCFI was censored at the date of last follow-up visit or date of death without prior breast cancer event.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">4884</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Continuous letrozole</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Continuous letrozole: 5 years continuously (2.5 mg Letrozole daily)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intermittent letrozole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intermittent letrozole: 48 months over 5 yrs: 4 x 9 months (9 mo followed by 3 mo treatment-free interval in yrs 1-4, -&gt; 36 mo) plus 1 x 12 mo in yr 5 -&gt; 48 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Letrozole</intervention_name>
    <description>Film-coated tablet, oral use, 2.5 mg Letrozole daily for 5 years continuously</description>
    <arm_group_label>Continuous letrozole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Letrozole</intervention_name>
    <description>Film-coated tablet, oral use, 2.5 mg daily, 48 months over 5 yrs: 4 x 9 months (9 mo followed by 3 mo treatment-free interval in yrs 1-4, -&gt; 36 mo) plus 1 x 12 mo in yr 5 -&gt; 48 months</description>
    <arm_group_label>Intermittent letrozole</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Confirmed diagnosis of prior operable, noninflammatory breast cancer meeting the
             following criteria:

               -  Steroid hormone receptor-positive tumors (estrogen receptor and/or progesterone
                  receptor), determined by immunohistochemistry, after primary surgery and before
                  commencement of prior endocrine therapy

               -  Prior local treatment including surgery with or without radiotherapy for primary
                  breast cancer with no known clinical residual loco-regional disease

               -  Following primary surgery, eligible patients must have had evidence of lymph node
                  involvement either in the axillary or internal mammary nodes, but not
                  supraclavicular nodes

               -  Clinically disease-free

          -  Must have completed 4-6 years of prior adjuvant selective estrogen receptor modulators
             (SERMs), aromatase inhibitors (AIs), or a sequential combination of both

               -  When calculating 4-6 years, neoadjuvant endocrine therapy should not be included

          -  No evidence of recurrent disease or distant metastatic disease

          -  No prior bilateral breast cancer

        PATIENT CHARACTERISTICS:

          -  Female

          -  Must be postmenopausal by any of the following criteria:

               -  Patients of any age who have had a bilateral oophorectomy (including radiation
                  castration AND amenorrheic for &gt; 3 months)

               -  Patients 56 years old or older with any evidence of ovarian function must have
                  biochemical evidence of definite postmenopausal status (defined as estradiol,
                  luteinizing hormone [LH], and follicle-stimulating hormone [FSH] in the
                  postmenopausal range)

               -  Patients 55 years old or younger must have biochemical evidence of definite
                  postmenopausal status (defined as estradiol, LH, and FSH in the postmenopausal
                  range)

                    -  Patients who have received prior luteinizing-hormone releasing-hormone
                       (LHRH) analogues within the last year are eligible if they have definite
                       evidence of postmenopausal status as defined above

          -  Clinically adequate hepatic function

          -  No bone fracture due to osteoporosis at any time during the 4-6 years of prior therapy

          -  No prior or current malignancy except adequately treated basal cell or squamous cell
             carcinoma of the skin, in situ carcinoma of the cervix or bladder, or contra- or
             ipsilateral in situ breast carcinoma

          -  No other nonmalignant systemic diseases (cardiovascular, renal, lung, etc.) that would
             prevent prolonged follow-up

          -  No psychiatric, addictive, or any other disorder that compromises compliance with
             protocol requirements

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  More than 12 months since prior and no other concurrent endocrine SERM/AI therapy

          -  Any type of prior adjuvant therapy allowed including, but not limited to, any of the
             following:

               -  Neoadjuvant chemotherapy

               -  Neoadjuvant endocrine therapy

               -  Adjuvant chemotherapy

               -  Trastuzumab (HerceptinÂ®)

               -  Ovarian ablation

               -  Gonadotropin releasing hormone analogues

               -  Lapatinib ditosylate

          -  No concurrent hormone-replacement therapy, bisphosphonates (except for treatment of
             bone loss), or any other investigational agent
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marco Colleoni, MD</last_name>
    <role>Study Chair</role>
    <affiliation>European Institute of Oncology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Faulkner Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02130-3400</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Armidale Hospital</name>
      <address>
        <city>Armidale</city>
        <state>New South Wales</state>
        <zip>2350</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bankstown - Lidcombe Hospital</name>
      <address>
        <city>Bankstown</city>
        <state>New South Wales</state>
        <zip>2200</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern Highlands Cancer Center</name>
      <address>
        <city>Bowral</city>
        <state>New South Wales</state>
        <zip>2576</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Concord Repatriation General Hospital</name>
      <address>
        <city>Concord</city>
        <state>New South Wales</state>
        <zip>2139</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Breast Center</name>
      <address>
        <city>Gateshead</city>
        <state>New South Wales</state>
        <zip>2290</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Port Mcquarie Base Hospital</name>
      <address>
        <city>Port Macquarie</city>
        <state>New South Wales</state>
        <zip>2444</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prince of Wales Private Hospital</name>
      <address>
        <city>Randwick</city>
        <state>New South Wales</state>
        <zip>2031</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tamworth Base Hospital</name>
      <address>
        <city>Tamworth</city>
        <state>New South Wales</state>
        <zip>2340</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tweed Heads Hospital</name>
      <address>
        <city>Tweed Heads</city>
        <state>New South Wales</state>
        <zip>2485</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Calvary Mater Newcastle</name>
      <address>
        <city>Waratah</city>
        <state>New South Wales</state>
        <zip>2310</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North West Regional Hospital</name>
      <address>
        <city>Burnie</city>
        <state>Tasmania</state>
        <zip>7320</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Hobart Hospital</name>
      <address>
        <city>Hobart</city>
        <state>Tasmania</state>
        <zip>7000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Box Hill Hospital</name>
      <address>
        <city>Box Hill</city>
        <state>Victoria</state>
        <zip>3128</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peter MacCallum Cancer Centre</name>
      <address>
        <city>East Melbourne</city>
        <state>Victoria</state>
        <zip>3002</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Austin Health</name>
      <address>
        <city>Heidelberg</city>
        <state>Victoria</state>
        <zip>3084</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maroondah Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3135</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Perth Hospital</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <zip>6000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Landeskrankenhaus Feldkirch</name>
      <address>
        <city>Feldkirch</city>
        <zip>A-6807</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Universitaet Graz</name>
      <address>
        <city>Graz</city>
        <zip>A-8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Innsbruck Universitaetsklinik</name>
      <address>
        <city>Innsbruck</city>
        <zip>A-6020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus BHS Linz</name>
      <address>
        <city>Linz</city>
        <zip>A-4010</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allgemeines Krankenhaus Linz</name>
      <address>
        <city>Linz</city>
        <zip>A-4021</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Johanns-Spital</name>
      <address>
        <city>Salzburg</city>
        <zip>A-5020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allgemeines Krankenhaus - Universitatskliniken</name>
      <address>
        <city>Vienna</city>
        <zip>A-1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Lainz</name>
      <address>
        <city>Vienna</city>
        <zip>A-1130</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hanusch-Krankenhaus</name>
      <address>
        <city>Vienna</city>
        <zip>A-1140</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LKH Villach</name>
      <address>
        <city>Villach</city>
        <zip>9500</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Kreuzschwestern Wels GmbH</name>
      <address>
        <city>Wels</city>
        <zip>4600</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ziekenhuis Netwerk Antwerpen Middelheim</name>
      <address>
        <city>Antwerpen</city>
        <zip>B-2020</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cliniques du Sud Luxembourg</name>
      <address>
        <city>Arlon</city>
        <zip>6700</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Imelda vzw, Ziekenhuis</name>
      <address>
        <city>Bonheiden</city>
        <zip>2820</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ Klina</name>
      <address>
        <city>Brasschaat</city>
        <zip>2930</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Jules Bordet</name>
      <address>
        <city>Brussels</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academisch Ziekenhuis der Vrije Universiteit Brussel</name>
      <address>
        <city>Brussels</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires Saint-Luc</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Brugmann</name>
      <address>
        <city>Brussels</city>
        <zip>B 1020</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Algemeen Ziekenhuis Sint-Maarten - Campus Rooiberg</name>
      <address>
        <city>Duffel</city>
        <zip>2570</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Gent</name>
      <address>
        <city>Ghent</city>
        <zip>B-9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital de Jolimont</name>
      <address>
        <city>Haine Saint Paul</city>
        <zip>7100</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virga Jesse Hospital</name>
      <address>
        <city>Hasselt</city>
        <zip>3500</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Hutois</name>
      <address>
        <city>Huy</city>
        <zip>4500</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ Groeninge - Oncologisch Centrum</name>
      <address>
        <city>Kortrijk</city>
        <zip>8500</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.Z. Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <zip>B-3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de l'Ardenne</name>
      <address>
        <city>Libramont</city>
        <zip>6800</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Regional de la Citadelle</name>
      <address>
        <city>Liege</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Saint-Joseph</name>
      <address>
        <city>Liege</city>
        <zip>B 4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Liege - Domaine Universitaire du Sart Tilman</name>
      <address>
        <city>Liege</city>
        <zip>B-4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jan Palfijn Hospital</name>
      <address>
        <city>Merksem</city>
        <zip>B-2170</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ Damiaan</name>
      <address>
        <city>Oostende</city>
        <zip>8400</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Saint-Pierre</name>
      <address>
        <city>Ottignies</city>
        <zip>B-1340</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Saint Vincent</name>
      <address>
        <city>Rocourt</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ Nikolaas - Sint-Niklaas</name>
      <address>
        <city>Sint-Niklaas</city>
        <zip>9100</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sint-Elisabethziekenhuis</name>
      <address>
        <city>Turnhout</city>
        <zip>2300</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Peltzer-La Tourelle</name>
      <address>
        <city>Verviers</city>
        <zip>B-4800</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Santiago Oriente Dr. Luis Tisne Brousse</name>
      <address>
        <city>Penalolen</city>
        <zip>2005</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundacion Arturo Lopez Perez</name>
      <address>
        <city>Santiago</city>
        <zip>29</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico San Borja Arriaran</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional Del Cancer</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRAM - Chile</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Regional de Valdivia at University Austral de Chile</name>
      <address>
        <city>Valdivia</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Carlos Van Buren</name>
      <address>
        <city>Valparaiso</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aarhus Universitetshospital - Aarhus Sygehus</name>
      <address>
        <city>Aarhus C</city>
        <zip>DK-8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Copenhagen County Herlev University Hospital</name>
      <address>
        <city>Copenhagen</city>
        <zip>DK-2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centralsygehus Esbjerg</name>
      <address>
        <city>Esbjerg</city>
        <zip>DK-6700</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herning Central Hospital</name>
      <address>
        <city>Herning</city>
        <zip>DK-7400</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hillerod Hospital</name>
      <address>
        <city>Hillerod</city>
        <zip>3400</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Naestved Hospital</name>
      <address>
        <city>Naestved</city>
        <zip>4700</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <zip>DK-5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bornholms Hospital</name>
      <address>
        <city>Ronne</city>
        <zip>3700</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roskilde Amtssygehuset</name>
      <address>
        <city>Roskilde</city>
        <zip>4000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sonderborg Sygehus</name>
      <address>
        <city>Sonderborg</city>
        <zip>6400</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vejle Sygehus</name>
      <address>
        <city>Vejle</city>
        <zip>DK-7100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Viborg Sygehus</name>
      <address>
        <city>Viborg</city>
        <zip>8800</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Bergonie</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aalen Breast Center</name>
      <address>
        <city>Aalen</city>
        <zip>73430</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onkologische Schwerpunktpraxis Bielefeld</name>
      <address>
        <city>Bielefeld</city>
        <zip>D-33602</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allgemeinen Krankenhaus Celle Kinderklinik</name>
      <address>
        <city>Celle</city>
        <zip>29223</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Deggendorf</name>
      <address>
        <city>Deggendorf</city>
        <zip>94469</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Wilke - Onkologie am Klinikum Fuerth</name>
      <address>
        <city>Fuerth</city>
        <zip>90766</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vinzenzkrankenhaus Hannover gGmbH</name>
      <address>
        <city>Hannover</city>
        <zip>30559</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henriettenstiftung Krankenhaus</name>
      <address>
        <city>Hannover</city>
        <zip>D-30171</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gynaekologisch-onkologische Praxis Hannover</name>
      <address>
        <city>Hannover</city>
        <zip>D-30177</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Frauenheilkunde u. Geburtshilfe</name>
      <address>
        <city>Ilsede</city>
        <zip>31241</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asklepios Klinik Lich</name>
      <address>
        <city>Lich</city>
        <zip>D-35423</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis Gynaekologie &amp; Geburtshilfe</name>
      <address>
        <city>Mannheim</city>
        <zip>D68161</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Meiningen GmbH</name>
      <address>
        <city>Meiningen</city>
        <zip>98617</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Memmingen</name>
      <address>
        <city>Memmingen</city>
        <zip>87700</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Offenback GmbH</name>
      <address>
        <city>Offenbach</city>
        <zip>D-63069</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Deaconess Hospital</name>
      <address>
        <city>Schwabisch Hall</city>
        <zip>D-74523</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johanniter Kankenhaus Stendal</name>
      <address>
        <city>Stendal</city>
        <zip>39576</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SRH Zentralklinikum Suhl GmbH</name>
      <address>
        <city>Suhl</city>
        <zip>98527</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Tuebingen</name>
      <address>
        <city>Tuebingen</city>
        <zip>D-72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Institute of Oncology - Budapest</name>
      <address>
        <city>Budapest</city>
        <zip>1122</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szeged University</name>
      <address>
        <city>Szeged</city>
        <zip>H-6720</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tata Memorial Hospital</name>
      <address>
        <city>Mumbai</city>
        <zip>400012</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro di Riferimento Oncologico - Aviano</name>
      <address>
        <city>Aviano</city>
        <zip>33081</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale degli Infermi - ASL 12</name>
      <address>
        <city>Biella</city>
        <zip>13900</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Sanitaria di Bolzano</name>
      <address>
        <city>Bolzano</city>
        <zip>39100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spedali Civili di Brescia</name>
      <address>
        <city>Brescia</city>
        <zip>25123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A. Perrino Hospital</name>
      <address>
        <city>Brindisi</city>
        <zip>72100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Istituti Ospitalieri</name>
      <address>
        <city>Cremona</city>
        <zip>26100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori</name>
      <address>
        <city>Meldola</city>
        <zip>47014</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>European Institute of Oncology</name>
      <address>
        <city>Milan</city>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione Salvatore Maugeri</name>
      <address>
        <city>Pavia</city>
        <zip>I-27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Misericordia e Dolce Hospital</name>
      <address>
        <city>Prato</city>
        <zip>59100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Civile Rimini</name>
      <address>
        <city>Rimini</city>
        <zip>47900</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale di Circolo e Fondazione Macchi</name>
      <address>
        <city>Varese</city>
        <zip>21100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka Rosai Hospital</name>
      <address>
        <city>Sakai</city>
        <state>Osaka</state>
        <zip>1179-3</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sagara Hospital</name>
      <address>
        <city>Kagoshima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kumamoto University Faculty of Medical and Pharmaceutical Sciences</name>
      <address>
        <city>Kumamoto</city>
        <zip>860-8556</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyoto University Hospital</name>
      <address>
        <city>Kyoto</city>
        <zip>606-8507</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Niigata Cancer Center Hospital</name>
      <address>
        <city>Niigata</city>
        <zip>951-8566</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yao Municipal Hospital</name>
      <address>
        <city>Osaka</city>
        <zip>581-0069</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokyo Metropolitan - Komagome Hospital</name>
      <address>
        <city>Tokyo</city>
        <zip>113-8677</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christchurch Hospital</name>
      <address>
        <city>Christchurch</city>
        <zip>1</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Waikato Hospital</name>
      <address>
        <city>Hamilton</city>
        <zip>2020</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional de Enfermedades Neoplasicas</name>
      <address>
        <city>Lima</city>
        <zip>34</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Russian Academy of Medical Sciences Cancer Research Center</name>
      <address>
        <city>Moscow</city>
        <zip>115478</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tygerberg Hospital</name>
      <address>
        <city>Kapstadt</city>
        <zip>7505</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandton Oncology Medical Research</name>
      <address>
        <city>Sandton</city>
        <zip>2199</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vall d'Hebron University Hospital</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>M. D. Anderson International Espana SA</name>
      <address>
        <city>Madrid</city>
        <zip>28033</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Ramon y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Son Llatzer</name>
      <address>
        <city>Palma De Mallorca</city>
        <zip>07198</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Sant Joan de Reus</name>
      <address>
        <city>Reus</city>
        <zip>43201</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen Macarena</name>
      <address>
        <city>Sevilla</city>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Torrevieja</name>
      <address>
        <city>Torrevieja</city>
        <zip>03180</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Valenciano De Oncologia</name>
      <address>
        <city>Valencia</city>
        <zip>46009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lasarettet i Boras</name>
      <address>
        <city>Boras</city>
        <zip>501 15</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Malarsjukhuset Hospital</name>
      <address>
        <city>Eskilstuna</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sahlgrenska University Hospital</name>
      <address>
        <city>Gothenburg</city>
        <zip>S-413 45</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lidkoping Hospital</name>
      <address>
        <city>Lidkoping</city>
        <zip>S-53185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skaraborgs Hospital</name>
      <address>
        <city>Skovde</city>
        <zip>541 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karolinska University Hospital - Huddinge</name>
      <address>
        <city>Stockholm</city>
        <zip>S-141 86</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Aarau</name>
      <address>
        <city>Aarau</city>
        <zip>CH-5001</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Baden</name>
      <address>
        <city>Baden</city>
        <zip>CH-5404</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Oncologico della Svizzera Italiana - Ospedale San Giovanni</name>
      <address>
        <city>Bellinzona</city>
        <zip>CH-6500</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inselspital Bern</name>
      <address>
        <city>Bern</city>
        <zip>CH-3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncocare Sonnenhof-Klinik Engeriedspital</name>
      <address>
        <city>Bern</city>
        <zip>CH-3012</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AndreasKlinik Cham Zug</name>
      <address>
        <city>Cham</city>
        <zip>CH-6330</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Graubuenden</name>
      <address>
        <city>Chur</city>
        <zip>CH-7000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brustzentrum Thurgau at Kantonsspital Frauenfeld</name>
      <address>
        <city>Frauenfeld</city>
        <zip>8501</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Freiburg</name>
      <address>
        <city>Freiburg</city>
        <zip>1708</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Vaudois</name>
      <address>
        <city>Lausanne</city>
        <zip>CH-1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lago Maggiore Oncology Foundation</name>
      <address>
        <city>Locarno</city>
        <zip>6600</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale &quot;la Carita&quot;, Locarno</name>
      <address>
        <city>Locarno</city>
        <zip>6600</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Civico</name>
      <address>
        <city>Lugano</city>
        <zip>CH-6903</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Beata Vergine</name>
      <address>
        <city>Mendrisio</city>
        <zip>CH-6850</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Olten</name>
      <address>
        <city>Olten</city>
        <zip>CH-4600</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Regional de Sion-Herens-Conthey</name>
      <address>
        <city>Sion</city>
        <zip>CH -1951</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tumor Zentrum ZeTup St. Gallen und Chur</name>
      <address>
        <city>St. Gallen</city>
        <zip>CH-9006</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital - St. Gallen</name>
      <address>
        <city>St. Gallen</city>
        <zip>CH-9007</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regionalspital</name>
      <address>
        <city>Thun</city>
        <zip>3600</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Winterthur</name>
      <address>
        <city>Winterthur</city>
        <zip>CH-8400</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Breast Center</name>
      <address>
        <city>Zurich</city>
        <zip>CH-8008</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Hospital Triemli</name>
      <address>
        <city>Zurich</city>
        <zip>CH-8063</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UniversitaetsSpital Zuerich</name>
      <address>
        <city>Zurich</city>
        <zip>CH-8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Borders General Hospital</name>
      <address>
        <city>Melrose</city>
        <state>England</state>
        <zip>TD6 9BS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dumfries &amp; Galloway Royal Infirmary</name>
      <address>
        <city>Dumfries</city>
        <state>Scotland</state>
        <zip>DG1 4AP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Chile</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>India</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>New Zealand</country>
    <country>Peru</country>
    <country>Russian Federation</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>November 2, 2007</study_first_submitted>
  <study_first_submitted_qc>November 2, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 4, 2007</study_first_posted>
  <results_first_submitted>January 4, 2019</results_first_submitted>
  <results_first_submitted_qc>January 4, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">January 29, 2019</results_first_posted>
  <last_update_submitted>March 9, 2020</last_update_submitted>
  <last_update_submitted_qc>March 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage IA breast cancer</keyword>
  <keyword>stage IB breast cancer</keyword>
  <keyword>stage II breast cancer</keyword>
  <keyword>stage IIIA breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Letrozole</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 6, 2007</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/10/NCT00553410/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 25, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/10/NCT00553410/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Arm A: Continuous Letrozole</title>
          <description>Continuous letrozole: 5 years continuously (2.5 mg Letrozole daily)
Letrozole: Film-coated tablet, oral use, 2.5 mg Letrozole daily for 5 years continuously</description>
        </group>
        <group group_id="P2">
          <title>Arm B: Intermittent Letrozole</title>
          <description>Intermittent letrozole: 48 months over 5 yrs: 4 x 9 months (9 mo followed by 3 mo treatment-free interval in yrs 1-4, -&gt; 36 mo) plus 1 x 12 mo in yr 5 -&gt; 48 months
Letrozole: Film-coated tablet, oral use, 2.5 mg daily, 48 months over 5 yrs: 4 x 9 months (9 mo followed by 3 mo treatment-free interval in yrs 1-4, -&gt; 36 mo) plus 1 x 12 mo in yr 5 -&gt; 48 months</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2441"/>
                <participants group_id="P2" count="2443"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2426"/>
                <participants group_id="P2" count="2425"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Randomized patients, regardless of eligibility status; exceptions were patients who immediately withdrew consent prior to treatment initiation and declined all participation, patients determined to be without adequate documentation of informed consent, and/or patients at a participating center determined not to be compliant with protocol procedures</population>
      <group_list>
        <group group_id="B1">
          <title>Arm A: Continuous Letrozole</title>
          <description>Continuous letrozole: 5 years continuously (2.5 mg Letrozole daily)
Letrozole: Film-coated tablet, oral use, 2.5 mg Letrozole daily for 5 years continuously</description>
        </group>
        <group group_id="B2">
          <title>Arm B: Intermittent Letrozole</title>
          <description>Intermittent letrozole: 48 months over 5 yrs: 4 x 9 months (9 mo followed by 3 mo treatment-free interval in yrs 1-4, -&gt; 36 mo) plus 1 x 12 mo in yr 5 -&gt; 48 months
Letrozole: Film-coated tablet, oral use, 2.5 mg daily, 48 months over 5 yrs: 4 x 9 months (9 mo followed by 3 mo treatment-free interval in yrs 1-4, -&gt; 36 mo) plus 1 x 12 mo in yr 5 -&gt; 48 months</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2426"/>
            <count group_id="B2" value="2425"/>
            <count group_id="B3" value="4851"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>&lt;55</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="668"/>
                    <measurement group_id="B2" value="671"/>
                    <measurement group_id="B3" value="1339"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>55-59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="504"/>
                    <measurement group_id="B2" value="496"/>
                    <measurement group_id="B3" value="1000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>60-64</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="451"/>
                    <measurement group_id="B2" value="471"/>
                    <measurement group_id="B3" value="922"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>65-69</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="400"/>
                    <measurement group_id="B2" value="375"/>
                    <measurement group_id="B3" value="775"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>70+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="383"/>
                    <measurement group_id="B2" value="412"/>
                    <measurement group_id="B3" value="795"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2426"/>
                    <measurement group_id="B2" value="2425"/>
                    <measurement group_id="B3" value="4851"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White/Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2199"/>
                    <measurement group_id="B2" value="2211"/>
                    <measurement group_id="B3" value="4410"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="119"/>
                    <measurement group_id="B2" value="121"/>
                    <measurement group_id="B3" value="240"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="97"/>
                    <measurement group_id="B2" value="83"/>
                    <measurement group_id="B3" value="180"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hungary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="78"/>
                    <measurement group_id="B2" value="77"/>
                    <measurement group_id="B3" value="155"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Japan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="93"/>
                    <measurement group_id="B2" value="99"/>
                    <measurement group_id="B3" value="192"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="217"/>
                    <measurement group_id="B2" value="216"/>
                    <measurement group_id="B3" value="433"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Switzerland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="159"/>
                    <measurement group_id="B2" value="159"/>
                    <measurement group_id="B3" value="318"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>India</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Russia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="137"/>
                    <measurement group_id="B2" value="134"/>
                    <measurement group_id="B3" value="271"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New Zealand</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Austria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="88"/>
                    <measurement group_id="B2" value="92"/>
                    <measurement group_id="B3" value="180"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sweden</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="104"/>
                    <measurement group_id="B2" value="105"/>
                    <measurement group_id="B3" value="209"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Belgium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="509"/>
                    <measurement group_id="B2" value="520"/>
                    <measurement group_id="B3" value="1029"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Denmark</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="223"/>
                    <measurement group_id="B2" value="218"/>
                    <measurement group_id="B3" value="441"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="287"/>
                    <measurement group_id="B2" value="291"/>
                    <measurement group_id="B3" value="578"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>South Africa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="182"/>
                    <measurement group_id="B2" value="171"/>
                    <measurement group_id="B3" value="353"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chile</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70"/>
                    <measurement group_id="B2" value="70"/>
                    <measurement group_id="B3" value="140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Peru</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="146"/>
                    <measurement group_id="B2" value="145"/>
                    <measurement group_id="B3" value="291"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Disease-free Survival (DFS)</title>
        <description>Duration of time from randomization to the first indication of the following events: invasive recurrence at local (including recurrence restricted to the breast after breast conserving treatment), regional or distant sites; a new invasive cancer in the contralateral breast; any second (non-breast) invasive malignancy; or a death without prior cancer event. Appearance of DCIS or LCIS either in the ipsilateral or in the contralateral breast was not be considered as an event for DFS. In the absence of an event, DFS was censored at the date of last follow-up visit.</description>
        <time_frame>5-year estimates, reported at a median follow-up of 60 months</time_frame>
        <population>Intention-to-treat</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: Continuous Letrozole</title>
            <description>Continuous letrozole: 5 years continuously (2.5 mg Letrozole daily)
Letrozole: Film-coated tablet, oral use, 2.5 mg Letrozole daily for 5 years continuously</description>
          </group>
          <group group_id="O2">
            <title>Arm B: Intermittent Letrozole</title>
            <description>Intermittent letrozole: 48 months over 5 yrs: 4 x 9 months (9 mo followed by 3 mo treatment-free interval in yrs 1-4, -&gt; 36 mo) plus 1 x 12 mo in yr 5 -&gt; 48 months
Letrozole: Film-coated tablet, oral use, 2.5 mg daily, 48 months over 5 yrs: 4 x 9 months (9 mo followed by 3 mo treatment-free interval in yrs 1-4, -&gt; 36 mo) plus 1 x 12 mo in yr 5 -&gt; 48 months</description>
          </group>
        </group_list>
        <measure>
          <title>Disease-free Survival (DFS)</title>
          <description>Duration of time from randomization to the first indication of the following events: invasive recurrence at local (including recurrence restricted to the breast after breast conserving treatment), regional or distant sites; a new invasive cancer in the contralateral breast; any second (non-breast) invasive malignancy; or a death without prior cancer event. Appearance of DCIS or LCIS either in the ipsilateral or in the contralateral breast was not be considered as an event for DFS. In the absence of an event, DFS was censored at the date of last follow-up visit.</description>
          <population>Intention-to-treat</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2426"/>
                <count group_id="O2" value="2425"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.5" lower_limit="86" upper_limit="88.8"/>
                    <measurement group_id="O2" value="85.8" lower_limit="84.2" upper_limit="87.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.31</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.08</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>.93</ci_lower_limit>
            <ci_upper_limit>1.26</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>Duration of time from randomization to death from any cause, or was censored at the date last known alive. (Note, for patients who withdrew consent or were lost to follow-up but follow-up for survival was possible through hospital or registry records, OS was censored at the date last known alive rather than date of last follow-up/withdrawn consent).</description>
        <time_frame>5-year estimates, reported at a median follow-up of 60 months</time_frame>
        <population>Intention-to-treat</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: Continuous Letrozole</title>
            <description>Continuous letrozole: 5 years continuously (2.5 mg Letrozole daily)
Letrozole: Film-coated tablet, oral use, 2.5 mg Letrozole daily for 5 years continuously</description>
          </group>
          <group group_id="O2">
            <title>Arm B: Intermittent Letrozole</title>
            <description>Intermittent letrozole: 48 months over 5 yrs: 4 x 9 months (9 mo followed by 3 mo treatment-free interval in yrs 1-4, -&gt; 36 mo) plus 1 x 12 mo in yr 5 -&gt; 48 months
Letrozole: Film-coated tablet, oral use, 2.5 mg daily, 48 months over 5 yrs: 4 x 9 months (9 mo followed by 3 mo treatment-free interval in yrs 1-4, -&gt; 36 mo) plus 1 x 12 mo in yr 5 -&gt; 48 months</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>Duration of time from randomization to death from any cause, or was censored at the date last known alive. (Note, for patients who withdrew consent or were lost to follow-up but follow-up for survival was possible through hospital or registry records, OS was censored at the date last known alive rather than date of last follow-up/withdrawn consent).</description>
          <population>Intention-to-treat</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2426"/>
                <count group_id="O2" value="2425"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.7" lower_limit="92.6" upper_limit="94.7"/>
                    <measurement group_id="O2" value="94.3" lower_limit="93.2" upper_limit="95.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.16</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>.85</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>.68</ci_lower_limit>
            <ci_upper_limit>1.06</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Distant Recurrence-free Interval (DRFI)</title>
        <description>Duration of time from randomization to the first indication of invasive breast recurrence at a distant site. In the absence of an event, DRFI was censored at the date of last follow-up visit or date or death without distant recurrence.*
*This endpoint replaced DDFS, which was specified in the protocol</description>
        <time_frame>5-year estimates, reported at a median follow-up of 60 months</time_frame>
        <population>Intention-to-treat</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: Continuous Letrozole</title>
            <description>Continuous letrozole: 5 years continuously (2.5 mg Letrozole daily)
Letrozole: Film-coated tablet, oral use, 2.5 mg Letrozole daily for 5 years continuously</description>
          </group>
          <group group_id="O2">
            <title>Arm B: Intermittent Letrozole</title>
            <description>Intermittent letrozole: 48 months over 5 yrs: 4 x 9 months (9 mo followed by 3 mo treatment-free interval in yrs 1-4, -&gt; 36 mo) plus 1 x 12 mo in yr 5 -&gt; 48 months
Letrozole: Film-coated tablet, oral use, 2.5 mg daily, 48 months over 5 yrs: 4 x 9 months (9 mo followed by 3 mo treatment-free interval in yrs 1-4, -&gt; 36 mo) plus 1 x 12 mo in yr 5 -&gt; 48 months</description>
          </group>
        </group_list>
        <measure>
          <title>Distant Recurrence-free Interval (DRFI)</title>
          <description>Duration of time from randomization to the first indication of invasive breast recurrence at a distant site. In the absence of an event, DRFI was censored at the date of last follow-up visit or date or death without distant recurrence.*
*This endpoint replaced DDFS, which was specified in the protocol</description>
          <population>Intention-to-treat</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2426"/>
                <count group_id="O2" value="2425"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.5" lower_limit="91.3" upper_limit="93.5"/>
                    <measurement group_id="O2" value="93.2" lower_limit="92" upper_limit="94.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.25</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>.88</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>.71</ci_lower_limit>
            <ci_upper_limit>1.09</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Breast Cancer-free Interval</title>
        <description>Duration of time from randomization to the first indication of the following events: invasive breast recurrence at local, regional or distant sites; a new invasive cancer in the contralateral breast (second non-breast malignancies are ignored). In the absence of an event, BCFI was censored at the date of last follow-up visit or date of death without prior breast cancer event.</description>
        <time_frame>5-year estimates, reported at a median follow-up of 60 months</time_frame>
        <population>Intention-to-treat</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: Continuous Letrozole</title>
            <description>Continuous letrozole: 5 years continuously (2.5 mg Letrozole daily)
Letrozole: Film-coated tablet, oral use, 2.5 mg Letrozole daily for 5 years continuously</description>
          </group>
          <group group_id="O2">
            <title>Arm B: Intermittent Letrozole</title>
            <description>Intermittent letrozole: 48 months over 5 yrs: 4 x 9 months (9 mo followed by 3 mo treatment-free interval in yrs 1-4, -&gt; 36 mo) plus 1 x 12 mo in yr 5 -&gt; 48 months
Letrozole: Film-coated tablet, oral use, 2.5 mg daily, 48 months over 5 yrs: 4 x 9 months (9 mo followed by 3 mo treatment-free interval in yrs 1-4, -&gt; 36 mo) plus 1 x 12 mo in yr 5 -&gt; 48 months</description>
          </group>
        </group_list>
        <measure>
          <title>Breast Cancer-free Interval</title>
          <description>Duration of time from randomization to the first indication of the following events: invasive breast recurrence at local, regional or distant sites; a new invasive cancer in the contralateral breast (second non-breast malignancies are ignored). In the absence of an event, BCFI was censored at the date of last follow-up visit or date of death without prior breast cancer event.</description>
          <population>Intention-to-treat</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2426"/>
                <count group_id="O2" value="2425"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.2" lower_limit="89.9" upper_limit="92.3"/>
                    <measurement group_id="O2" value="90.9" lower_limit="89.6" upper_limit="92.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.84</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>.98</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>.81</ci_lower_limit>
            <ci_upper_limit>1.18</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>during or within 30 days after stopping study treatment</time_frame>
      <desc>Adverse event is defined as any untoward medical occurrence that occurs from the first dose of study medication until 30 days after final dose, regardless of whether it is considered related to a medication. Any known untoward event that occurs subsequent to the adverse event reporting period that the investigator assesses as possibly related to the protocol treatment should be considered an adverse event. Symptoms of the targeted cancer (if applicable) should not be reported as adverse events.</desc>
      <group_list>
        <group group_id="E1">
          <title>Arm A: Continuous Letrozole</title>
          <description>Continuous letrozole: 5 years continuously (2.5 mg Letrozole daily)
Letrozole: Film-coated tablet, oral use, 2.5 mg Letrozole daily for 5 years continuously</description>
        </group>
        <group group_id="E2">
          <title>Arm B: Intermittent Letrozole</title>
          <description>Intermittent letrozole: 48 months over 5 yrs: 4 x 9 months (9 mo followed by 3 mo treatment-free interval in yrs 1-4, -&gt; 36 mo) plus 1 x 12 mo in yr 5 -&gt; 48 months
Letrozole: Film-coated tablet, oral use, 2.5 mg daily, 48 months over 5 yrs: 4 x 9 months (9 mo followed by 3 mo treatment-free interval in yrs 1-4, -&gt; 36 mo) plus 1 x 12 mo in yr 5 -&gt; 48 months</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>NCI CTCAE V.3</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="170" subjects_at_risk="2426"/>
                <counts group_id="E2" subjects_affected="146" subjects_at_risk="2425"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1004" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="1052" subjects_at_risk="2417"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2417"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac Arrhythmia-Other (Specify)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Cardiac-ischemia/infarction</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Conduction abnormality/Atrioventricular heart block - AV block-2nd degree Mobitz Type I (Wenckebach)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Conduction abnormality/Atrioventricular heart block - AV block-third degree (complete AV block)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Conduction abnormality/Atrioventricular heart block - Wolff-Parkinson-White syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Left ventricular diastolic dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Left ventricular systolic dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Pain - Cardiac/heart</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Pericardial effusion (non-malignant)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Restrictive cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Right ventricular dysfunction (cor pulmonale)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Supraventricular and nodal arrhythmia - Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Supraventricular and nodal arrhythmia - Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Supraventricular and nodal arrhythmia - Atrial tachycardia/paroxysmal atrial tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Supraventricular and nodal arrhythmia - Sinus bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Supraventricular and nodal arrhythmia - Supraventricular arrhythmia NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Supraventricular and nodal arrhythmia - Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Valvular heart disease</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Ventricular arrhythmia - Ventricular arrhythmia NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Ventricular arrhythmia - Ventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2417"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Auditory/Ear-Other (Specify)</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Hearing: patients without baseline audiogram and not enrolled in a monitoring program</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2417"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Thyroid function, high (hyperthyroidism, thyrotoxicosis)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Thyroid function, low (hypothyroidism)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Endocrine-Other (Specify)</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2417"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Dry eye syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Glaucoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Ocular/Visual-Other (Specify)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Ophthalmoplegia/diplopia (double vision)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Retinopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Vision-blurred vision</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Vision-photophobia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2417"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hemorrhage, GI - Colon</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Hemorrhage, GI - Upper GI NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Ileus, GI (functional obstruction of bowel, i.e., neuroconstipation)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Obstruction, GI - Cecum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Obstruction, GI - Esophagus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Obstruction, GI - Ileum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Obstruction, GI - Small bowel NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Ulcer, GI - Duodenum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Dental: teeth</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Dry mouth/salivary gland (xerostomia)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Dysphagia (difficulty swallowing)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Esophagitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Gastritis (including bile reflux gastritis)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Gastrointestinal-Other (Specify)</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Heartburn/dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Hemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Mucositis/stomatitis (clinical exam) - Anus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Pain - Abdomen NOS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Pain - Stomach</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2417"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue (asthenia, lethargy, malaise)</sub_title>
                <counts group_id="E1" subjects_affected="58" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="48" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Fever (in the absence of neutropenia, where neutropenia is defined as ANC &lt;1.0 x 10e9/L)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Constitutional Symptoms-Other (Specify)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Death not associated with CTCAE term - Death NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Death not associated with CTCAE term - Sudden death</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Pain - Chest/thorax NOS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Pain - Pain NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Pain-Other (Specify)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2417"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Obstruction, GI - Gallbladder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Stricture/stenosis (including anastomotic), GI - Biliary tree</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Hepatobiliary/Pancreas-Other (Specify)</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="2417"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic reaction/hypersensitivity (including drug fever)</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2417"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Colitis, infectious (e.g., Clostridium difficile)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils - Brain (encephalitis, infectious)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils - Foreign body (e.g., graft, implant)</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Infection with unknown ANC - Foreign body (e.g., graft, implant, prosthesis, stent)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Infection (documented clinically or microbiologically) w/Grade 3 or 4 neutrophils -Lung (pneumonia)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Infection (documented clinically or microbiologically) w/Grade 3 or 4 neutrophils -Small bowel NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils - Kidney</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils - Paranasal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils - Pharynx</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils - Abdomen NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils - Anal/perianal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils - Appendix</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils - Bladder (urinary)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils - Bone (osteomyelitis)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils - Brain + Spinal cord (encephalomyelitis)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils - Bronchus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils - Catheter-related</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils - Colon</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils - Gallbladder (cholecystitis)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils - Joint</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils - Kidney</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils - Lung (pneumonia)</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils - Lymphatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils - Nerve-peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils - Sinus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils - Skin (cellulitis)</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils - Small bowel NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils - Urinary tract NOS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils - Wound</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Infection with unknown ANC - Appendix</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Infection with unknown ANC - Dental-tooth</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Infection with unknown ANC - Larynx</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Infection with unknown ANC - Lung (pneumonia)</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Infection with unknown ANC - Skin (cellulitis)</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Infection with unknown ANC - Urinary tract NOS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Infection with unknown ANC - Wound</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Infection-Other (Specify)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Viral hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2417"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Wound complication, non-infectious</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" subjects_affected="66" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="62" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Intra-operative injury - Joint</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Intra-operative injury - Oral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Intra-operative injury - Spleen</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Local complication - device/prosthesis-related</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Seroma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Thrombosis/embolism (vascular access-related)</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Vessel injury-artery - Aorta</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Vessel injury-artery - Carotid</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2417"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>ALT, SGPT (serum glutamic pyruvic transaminase)</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Cholesterol, serum-high (hypercholesterolemia)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Coagulation-Other (Specify)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>GGT (gamma-glutamyl transpeptidase)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>INR (International Normalized Ratio of prothrombin time)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Lipase</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Metabolic/Laboratory-Other (Specify)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Platelets</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Weight gain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2417"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Glucose, serum-high (hyperglycemia)</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Potassium, serum-low (hypokalemia)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Sodium, serum-low (hyponatremia)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Obesity</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="2417"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthritis (non-septic)</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Fibrosis-deep connective tissue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Joint-function</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Lymphedema-related fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Musculoskeletal/Soft Tissue-Other (Specify)</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Osteonecrosis (avascular necrosis)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Osteoporosis</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Pain - Back</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Pain - Bone</sub_title>
                <counts group_id="E1" subjects_affected="58" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Pain - Chest wall</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Pain - Extremity-limb</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Pain - Joint</sub_title>
                <counts group_id="E1" subjects_affected="151" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="139" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Pain - Muscle</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="53" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Pain - Neck</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Soft tissue necrosis - Extremity-lower</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2417"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemorrhage, CNS</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Speech impairment (e.g., dysphasia or aphasia)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Ataxia (incoordination)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>CNS cerebrovascular ischemia</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Cognitive disturbance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Memory impairment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Mental status</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Myelitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Neurology-Other (Specify)</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Neuropathy: cranial - CN VII Motor-face; Sensory-taste</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Neuropathy: cranial - CN VIII Hearing and balance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Neuropathy: motor</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Neuropathy: sensory</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Pain - Head/headache</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Pain - Neuralgia/peripheral nerve</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Syncope (fainting)</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Vasovagal episode</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2417"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="59" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="52" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Mood alteration - anxiety</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Mood alteration - depression</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="61" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Psychosis (hallucinations/delusions)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2417"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hemorrhage, GU - Urinary NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Incontinence, urinary</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Obstruction, GU - Ureter</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Obstruction, GU - Urethra</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Renal/Genitourinary-Other (Specify)</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="2417"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Hemorrhage, GU - Vagina</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Pain - Pelvis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Sexual/Reproductive Function-Other (Specify)</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2417"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hemorrhage, pulmonary/upper respiratory - Lung</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Adult respiratory distress syndrome (ARDS)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Apnea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Aspiration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Dyspnea (shortness of breath)</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Obstruction/stenosis of airway - Bronchus</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Pleural effusion (non-malignant)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Pneumonitis/pulmonary infiltrates</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Pulmonary/Upper Respiratory-Other (Specify)</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="2417"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Urticaria (hives, welts, wheals)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Dermatology/Skin-Other (Specify)</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Nail changes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Pruritus/itching</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Rash/desquamation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2417"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Hemorrhage/Bleeding-Other (Specify)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Hot flashes/flushes</sub_title>
                <counts group_id="E1" subjects_affected="70" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="59" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="517" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="584" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Peripheral arterial ischemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Vascular-Other (Specify)</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Vasculitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2417"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>NCI CTCAE V.3</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2257" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="2261" subjects_at_risk="2417"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac-ischemia/infarction</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="2417"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue (asthenia, lethargy, malaise)</sub_title>
                <counts group_id="E1" subjects_affected="1025" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="954" subjects_at_risk="2417"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" subjects_affected="148" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="136" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Thrombosis/embolism (vascular access-related)</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="2417"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteoporosis</sub_title>
                <counts group_id="E1" subjects_affected="1113" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="1119" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Pain - Bone</sub_title>
                <counts group_id="E1" subjects_affected="634" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="613" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Pain - Joint</sub_title>
                <counts group_id="E1" subjects_affected="1506" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="1453" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Pain - Muscle</sub_title>
                <counts group_id="E1" subjects_affected="841" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="818" subjects_at_risk="2417"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemorrhage, CNS</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>CNS cerebrovascular ischemia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="2417"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="983" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="961" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Mood alteration - depression</sub_title>
                <counts group_id="E1" subjects_affected="767" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="762" subjects_at_risk="2417"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flashes/flushes</sub_title>
                <counts group_id="E1" subjects_affected="1240" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="1217" subjects_at_risk="2417"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="539" subjects_at_risk="2411"/>
                <counts group_id="E2" subjects_affected="493" subjects_at_risk="2417"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Meredith M. Regan</name_or_title>
      <organization>International Breast Cancer Study Group (IBCSG)</organization>
      <phone>+1 617 632 3012</phone>
      <email>mregan@jimmy.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

